Valentina Iacuzzi

Dr. Valentina Iacuzzi


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Bianca PosoccoBianca Posocco
Bianca Posocco
MBMauro Buzzo
Mauro Buzzo
APAriana Soledad Poetto
Ariana Soledad Poetto
MOMarco Orleni
Marco Orleni
SGSara Gagno
Sara Gagno
GTGiuseppe Toffoli
Giuseppe Toffoli
A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be applied in clinical practice due to the simple and fast sample preparation based on protein precipitation, the low amount of patient sample necessary for the analysis (10 μL) and the total run time of 6.5 min. It was fully validated according to FDA and EMA guidelines on bioanalytical method validation. The linearity was assessed (R2 within 0.9992–0.9983) over the concentration ranges of 0.3–250 ng/mL for palbociclib, 10–10000 ng/mL for ribociclib and 0.5–500 ng/mL for letrozole that properly cover the therapeutic plasma concentrations. A specific strategy was implemented to reduce the carryover phenomenon, formerly known for these CDKIs. This method was applied to quantify the Cmin of palbociclib, ribociclib and letrozole in plasma samples from patients enrolled in a clinical study. The same set of study samples was analysed twice in separate runs to assess the reproducibility of the method by means of the incurred samples reanalysis. The results corroborated the reliability of the analyte concentrations obtained with the bioanalytical method, already proved by the validation process. The percentage differences were always within ±10% for all the analytes and the R2 of the correlation graph between the two quantifications was equal to 0.9994.

19 November 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VIValentina Iacuzzi
Valentina Iacuzzi
Bianca PosoccoBianca Posocco
Bianca Posocco
MZMartina Zanchetta
Martina Zanchetta
MMMarcella Montico
Marcella Montico
EMElena Marangon
Elena Marangon
GTGiuseppe Toffoli
Giuseppe Toffoli
The introduction of imatinib, an oral tyrosine kinase inhibitor, as first-line standard therapy in patients with unresectable, metastatic, or recurrent gastro-intestinal stromal tumor (GIST), strongly improved their treatment outcomes. However, therapeutic drug monitoring (TDM) is recommended for this drug due to the large inter-individual variability in plasma concentration when standard dose is administered. A Cmin higher than 760 ng/mL was associated with a longer progression free survival. Thus, a LC-MS/MS method has been developed and fully validated to quantify imatinib and its active metabolite, norimatinib, in finger-prick dried blood spot (DBS). The influence of hematocrit, sample homogeneity, and spot size and the correlation between finger-prick and venous DBS measurements were also assessed. The method showed a good linearity (R2 > 0,996) between 50–7500 ng/mL for imatinib and 10–1500 ng/mL for norimatinib. Analytes were extracted from DBS samples by simply adding to 3 mm-discs 150 μL of acidified methanol containing IMA-D8. The collected extract was then injected on a LC Nexera system in-house configured for the on-line cleanup, coupled with an API-4000 QT. The chromatographic separation was conducted on a Synergi Fusion-RP column (4 μm, 2x50 mm) while the trapping column was a POROS R1/20 (20 μm, 2x30 mm). The total run time was 8.5 min. DBSs stored at room temperature in plastic envelopes containing a silica-gel drying bag were stable up to 16 months. The proposed method was applied to 67 clinical samples, showing a good correlation between patients’ finger-prick DBS and plasma concentrations, measured by the reference LC-MS/MS method, internally validated. Imatinib and norimatinib concentrations found in finger-prick DBS were adjusted by hematocrit or by an experimental correction factor to estimate the corresponding plasma measurements. At the best of our knowledge, the proposed LC-MS/MS method is the first analytical assay to measure imatinib and norimatinib in DBS samples.

3 April 2019 in Small
Verified
Journal Article
Closed access
PDF file
DMDomenico Marson
Domenico Marson
FGFilomena Guida
Filomena Guida
MŞMaria Şologan
Maria Şologan
SBSilvia Boccardo
Silvia Boccardo
PPPaolo Pengo
Paolo Pengo
PPPAOLA POSOCCO
PAOLA POSOCCO

1 August 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
VIValentina Iacuzzi
Valentina Iacuzzi
MZMartina Zanchetta
Martina Zanchetta
SGSara Gagno
Sara Gagno
APAriana Soledad Poetto
Ariana Soledad Poetto
MOMarco Orleni
Marco Orleni
GTGiuseppe Toffoli
Giuseppe Toffoli


29 August 2020 in Nanomaterials
Verified
Journal Article
Open access
PDF file
Martina TommasiniMartina Tommasini
Martina Tommasini
EPElena Pellizzoni
Elena Pellizzoni
VIValentina Iacuzzi
Valentina Iacuzzi
EMElena Marangon
Elena Marangon
PPPAOLA POSOCCO
PAOLA POSOCCO
Federico BertiFederico Berti
Federico Berti
Fluorescent, imprinted nanosized polymers for the detection of irinotecan have been synthesised using a napthalimide polymerisable derivative (2-allyl-6-[2-(aminoethyl)-amino] napthalimide) as functional monomer. The imprinted polymers contain ethylene glycol dimethacrylate (EGDMA) as a cross-linker and were prepared by high dilution radical polymerisation in dimethylsulphoxide (DMSO). The material was able to rebind irinotecan up to 18 nmol/mg with good specificity. Fluorescence emission at 525 nm (excitation at 448 nm) was quenched by increasing concentrations of irinotecan via a static mechanism and also in analytically useful environments as mixtures of human plasma and organic solvents. This allowed the direct detection of irinotecan (in the 10–30 μM range) in human plasma treated with acetonitrile; the limit of detection (LOD) was 9.4 nM, with within-run variability of 10% and day-to-day variability of 13%.